Cargando…
Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
PURPOSE: Although expert guidelines for the treatment of schizophrenia recommend antipsychotic monotherapy, the use of antipsychotic polypharmacy is common. This study identified characteristics that differentiate patients with schizophrenia who are treated with olanzapine monotherapy versus polypha...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278200/ https://www.ncbi.nlm.nih.gov/pubmed/22347801 http://dx.doi.org/10.2147/CEOR.S25968 |
_version_ | 1782223537534140416 |
---|---|
author | Ye, Wenyu Ascher-Svanum, Haya Flynn, Jennifer A Tanji, Yuka Takahashi, Michihiro |
author_facet | Ye, Wenyu Ascher-Svanum, Haya Flynn, Jennifer A Tanji, Yuka Takahashi, Michihiro |
author_sort | Ye, Wenyu |
collection | PubMed |
description | PURPOSE: Although expert guidelines for the treatment of schizophrenia recommend antipsychotic monotherapy, the use of antipsychotic polypharmacy is common. This study identified characteristics that differentiate patients with schizophrenia who are treated with olanzapine monotherapy versus polypharmacy in usual care in Japan. PATIENTS AND METHODS: In a large (N = 1850) prospective, observational study, Japanese patients with schizophrenia who initiated treatment with olanzapine were followed for 1 year. Consistent with past research, antipsychotic polypharmacy was defined as the concurrent use of olanzapine and another antipsychotic for at least 60 days. Switching was defined as discontinuing a prior antipsychotic therapy rather than augmenting the medication regimen. Predictors of antipsychotic monotherapy were based on information available at the time of olanzapine initiation. Baseline characteristics were compared using t-tests and χ(2) tests. Stepwise logistic regression was used to identify independent predictors of monotherapy. RESULTS: Patients treated with olanzapine monotherapy (43.2%) differed from those treated with antipsychotic polypharmacy (56.8%) on demographics, treatment history, baseline symptom levels, functional levels, and treatment-emergent adverse events. Stepwise logistic regression identified multiple variables that significantly predicted monotherapy: older age, shorter duration of schizophrenia, outpatient status, comorbid medical conditions, lower body mass index, no prior anticholinergic use, no prior mood stabilizer use, and switching from a previous antipsychotic (typical or atypical). CONCLUSION: Consistent with prior research in Japan, antipsychotic polypharmacy appears to be common in the treatment of schizophrenia. Patients treated with monotherapy could be differentiated from those treated with antipsychotic polypharmacy based on a specific set of demographic and baseline clinical characteristics. |
format | Online Article Text |
id | pubmed-3278200 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-32782002012-02-17 Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan Ye, Wenyu Ascher-Svanum, Haya Flynn, Jennifer A Tanji, Yuka Takahashi, Michihiro Clinicoecon Outcomes Res Original Research PURPOSE: Although expert guidelines for the treatment of schizophrenia recommend antipsychotic monotherapy, the use of antipsychotic polypharmacy is common. This study identified characteristics that differentiate patients with schizophrenia who are treated with olanzapine monotherapy versus polypharmacy in usual care in Japan. PATIENTS AND METHODS: In a large (N = 1850) prospective, observational study, Japanese patients with schizophrenia who initiated treatment with olanzapine were followed for 1 year. Consistent with past research, antipsychotic polypharmacy was defined as the concurrent use of olanzapine and another antipsychotic for at least 60 days. Switching was defined as discontinuing a prior antipsychotic therapy rather than augmenting the medication regimen. Predictors of antipsychotic monotherapy were based on information available at the time of olanzapine initiation. Baseline characteristics were compared using t-tests and χ(2) tests. Stepwise logistic regression was used to identify independent predictors of monotherapy. RESULTS: Patients treated with olanzapine monotherapy (43.2%) differed from those treated with antipsychotic polypharmacy (56.8%) on demographics, treatment history, baseline symptom levels, functional levels, and treatment-emergent adverse events. Stepwise logistic regression identified multiple variables that significantly predicted monotherapy: older age, shorter duration of schizophrenia, outpatient status, comorbid medical conditions, lower body mass index, no prior anticholinergic use, no prior mood stabilizer use, and switching from a previous antipsychotic (typical or atypical). CONCLUSION: Consistent with prior research in Japan, antipsychotic polypharmacy appears to be common in the treatment of schizophrenia. Patients treated with monotherapy could be differentiated from those treated with antipsychotic polypharmacy based on a specific set of demographic and baseline clinical characteristics. Dove Medical Press 2012-01-13 /pmc/articles/PMC3278200/ /pubmed/22347801 http://dx.doi.org/10.2147/CEOR.S25968 Text en © 2012 Ye et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Ye, Wenyu Ascher-Svanum, Haya Flynn, Jennifer A Tanji, Yuka Takahashi, Michihiro Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan |
title | Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan |
title_full | Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan |
title_fullStr | Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan |
title_full_unstemmed | Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan |
title_short | Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan |
title_sort | predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in japan |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278200/ https://www.ncbi.nlm.nih.gov/pubmed/22347801 http://dx.doi.org/10.2147/CEOR.S25968 |
work_keys_str_mv | AT yewenyu predictorsofantipsychoticmonotherapywitholanzapineduringa1yearnaturalisticstudyofschizophreniapatientsinjapan AT aschersvanumhaya predictorsofantipsychoticmonotherapywitholanzapineduringa1yearnaturalisticstudyofschizophreniapatientsinjapan AT flynnjennifera predictorsofantipsychoticmonotherapywitholanzapineduringa1yearnaturalisticstudyofschizophreniapatientsinjapan AT tanjiyuka predictorsofantipsychoticmonotherapywitholanzapineduringa1yearnaturalisticstudyofschizophreniapatientsinjapan AT takahashimichihiro predictorsofantipsychoticmonotherapywitholanzapineduringa1yearnaturalisticstudyofschizophreniapatientsinjapan |